Quantification of serum apolipoprotein B by infrared spectroscopy

Kan-Zhi Liu; Man, Angela; Dembinski, Thomas C.; Shaw, R. Anthony
March 2007
Analytical & Bioanalytical Chemistry;Mar2007, Vol. 387 Issue 5, p1809
Academic Journal
While the conventional approach to assessing both the risk of coronary artery disease and the adequacy of therapy is LDL cholesterol testing, there is compelling evidence to suggest that apolipoprotein B (apoB) is superior to LDL cholesterol for both of these purposes. However, the measurement of apoB requires techniques that can be expensive and difficult to standardize. The aim of this study was, therefore, to develop a new method, based on infrared (IR) spectroscopy, for the routine quantification of apoB in human serum. A total of 366 serum samples were obtained from patients with various disorders. Small volumes (2 μl) of serum specimens were dried to films, and duplicate IR absorption spectra measured. The reference apoB concentrations were determined separately using a standard method, and the proposed IR method was then calibrated using partial least squares (PLS) regression analysis to quantitatively correlate the IR spectra with the reference results. The apoB concentrations predicted from the IR spectra of serum were highly correlated and in excellent agreement with those determined by the reference method. The correlation coefficient ( r) for apoB was 0.94, with the standard error between IR-predicted and reference values was 0.10 g/L. In combination with earlier work demonstrating the accurate determination of LDL-C, HDL-C, total cholesterol, and triglycerides from a single infrared spectroscopic measurement, the addition of accurate apoB determination from the same spectrum makes the method very attractive for laboratory use in the routine evaluation of coronary artery disease risk. [Figure not available: see fulltext.]


Related Articles

  • Conventional and Advanced Lipid Parameters in Premature Coronary Artery Disease Patients in India. BANSAL, SANJIV KUMAR; AGARWAL, SARITA; DAGA, MRIDUL KUMAR // Journal of Clinical & Diagnostic Research;Nov2015, Vol. 9 Issue 11, p7 

    Background: Coronary artery disease (CAD) is the leading cause of death worldwide and has assumed alarming proportions in India with gradual increase in its incidence and prevalence over the last decade. India is in the middle of epidemic of coronary artery disease which is leading cause of...

  • Apolipoprotein A-I Mimetic Peptides for the Treatment of Coronary Artery Disease. Yamada, Nicole K. // Current Cardiology Reviews;2005, Vol. 1 Issue 1, p81 

    High density lipoprotein (HDL) plays a critical physiological role in protecting the body against atherosclerosis by facilitating reverse cholesterol transport and the removal of oxidized phosphoplipids from artery walls. Apolipoprotein A-I (apoA-I) is the principal protein component of HDL that...

  • Lipoprotein(a) and Its Position among Other Risk Factors of Atherosclerosis. Zlatohlávek, L.; Zídková, K.; Vrablík, M.; Haas, T.; Prusíková, M.; Svobodová, H.; Češka, R. // Physiological Research;2008, Vol. 57 Issue 5, p777 

    Lipoprotein(a) [Lp(a)] comprises of an LDL particle and apolipoprotein(a) [apo(a)] and its elevated levels are considered a risk factor for atherosclerosis. The aim of our study was to find out whether elevated Lp(a) levels are associated with increased risk of atherosclerosis in patients with...

  • Türk halkında yeni geliÅŸen koroner hastalık öngördürücüsü olarak serum apolipoprotein B düzeyi LDL-kolesterolden üstün. Onat, Altan; Özhan, Hakan; Can, Günay; Hergenç, Gülay; Karabulut, Ahmet; Albayrak, Sinan // Anatolian Journal of Cardiology / Anadolu Kardiyoloji Dergisi;Jun2007, Vol. 7 Issue 2, p128 

    Objective: To investigate the relative roles of serum apolipoprotein (apo) B and low density lipoprotein (LDL)-cholesterol levels in predicting incident coronary heart disease (CHD). Whether apo B/apo A-I ratio has advantage over apo B in this prediction constitutes a secondary aim. Methods:...

  • Apolipoprotein B as a measure of lipoprotein apheresis efficacy. Neves, Emma; Pottle, Alison // British Journal of Cardiac Nursing;Nov2013, Vol. 8 Issue 11, p542 

    An elevated level of low-density lipoprotein cholesterol in the bloodstream has been considered a risk factor in the development of coronary heart disease for many years. Cholesterol-lowering medication, while usually successful, may prove insufficient and lipoprotein apheresis may be the...

  • Cloning, expression, purification, and quantification of the 17% Nterminal domain of apolipoprotein b-100. Khachfe, Hassan M.; Atkinson, David // Journal of Cell & Molecular Biology;Dec2011, Vol. 9 Issue 2, p37 

    Apolipoprotein B-100 (apo B) is the sole protein component of normal human low density lipoprotein (LDL). Elevated levels of LDL have been correlated with atherosclerosis and other coronary artery diseases. The large size of apo B (4536 aa) necessitates that it be studied in pieces corresponding...

  • Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading? Bays, Harold; Conard, Scott; Leiter, Lawrence A.; Bird, Steven; Jensen, Erin; Hanson, Mary E.; Shah, Arvind; Tershakovec, Andrew M. // Lipids in Health & Disease;2010, Vol. 9, p136 

    Background: Some patients administered cholesterol-lowering therapies may experience an increase in the proportion of small LDL particles, which may be misinterpreted as a worsening of atherosclerotic coronary heart disease risk. This study assessed the lipid effects of adding ezetimibe to...

  • Apolipoprotein E Polymorphism in Omani Dyslipidemic Patients With and Without Coronary Artery Disease. Al-Yahyaee, Said Alis S.; Ganguly, Shyam Sundar; Alkindi, Mohammed Nasser; Al-Bahrani, Ali Ihassan // Human Biology;Feb2007, Vol. 79 Issue 1, p93 

    Abstract Apolipoprotein E (APOE) polymorphism is a predictor of interindividual variability in plasma levels of lipids and lipoproteins and a predictor of risk of coronary artery disease (CAD). We studied the relationship between APOE polymorphism and lipid profiles and risk of CAD in Omani...

  • The important role for ßVLDLs binding at the fourth cysteine of first ligand-binding domain in the low-density lipoprotein receptor. Iwasaki, Tadao; Takahashi, Sadao; Ishihara, Mitsuaki; Takahashi, Masafumi; Ikeda, Uichi; Shimada, Kazuyuki; Fujino, Takahiro; Yamamoto, Tokuo; Hattori, Hiroaki; Emi, Mitsuru // Journal of Human Genetics;2004, Vol. 49 Issue 11, p622 

    The low-density lipoprotein (LDL) receptor (LDLR) is a crucial role for binding and uptaking apolipoprotein (apo) B-containing lipoproteins, such as very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), and LDL. The defect function of the LDLR causes familial...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics